MPS II Immunophenotyping
study id #: NCT04976231
condition: MPS II, Mucopolysaccharidosis II, Hunter Syndrome
status: Not yet recruiting
purpose:The purpose of this study is to investigate how participant’s body’s immune system responds to idursulfase, an enzyme replacement therapy (ERT) and find out which types of immune cells are involved in causing untoward responses to the ERT so that the investigators can relate the level of immune response to the treatment.
results: https://clinicaltrials.gov/ct2/show/results/NCT04976231
last updated: February 26, 2022
-
MPS I: Early Diagnosis, Bone Disease and Treatment, Where Are We NowMucopolysaccharidosis type I (MPS I) is ...
-
Long-Term Safety and Clinical Outcomes of Intrathecal Heparan-N-Sulfatase in Patients With Sanfilippo Syndrome Type ...Currently, there is no effective therapy...
-
Molecular Analysis and Novel Variation Identification of Chinese Pedigrees With Mucopolysaccharidosis Using Targeted...Mucopolysaccharidosis (MPS) refers to a ...
-
Iminosugar C-Glycosides Work as Pharmacological Chaperones of NAGLU, a Glycosidase Involved in MPS IIIB Rare DiseaseMucopolysaccharidosis type IIIB is a dev...
-
COVID-19 and MPS Patientshttps://www.youtube.com/watch?v=euwZ_vDW...
-
Mucopolysaccharidoses (MPS) and Gene TherapyMucopolysaccharidoses (MPS) are a group ...
-
Hearing Loss in MucopolysaccharidosisIntroduction: Mucopolysaccharidosis (MPS...